In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Adc Therapeutics SA (NYSE: ADCT) closed at $1.47 down -2.65% from its previous closing price of $1.51. In other words, the price has decreased by -$2.65 from its previous closing price. On the day, 0.52 million shares were traded. ADCT stock price reached its highest trading level at $1.51 during the session, while it also had its lowest trading level at $1.4206.
Ratios:
For a deeper understanding of Adc Therapeutics SA’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.68 and its Current Ratio is at 4.92.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share. On Dec 04 ’24, another insider, Redmile Group, LLC, who serves as the 10% Owner of the company, sold 25,352 shares for $2.07 each. As a result, the insider received 52,479 and left with 15,566,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 142133712 and an Enterprise Value of 322257728. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01. Its current Enterprise Value per Revenue stands at 4.557 whereas that against EBITDA is -2.355.
Stock Price History:
The Beta on a monthly basis for ADCT is 1.55, which has changed by -0.6421801 over the last 52 weeks, in comparison to a change of 0.21659255 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $6.04, while it has fallen to a 52-week low of $1.49. The 50-Day Moving Average of the stock is -25.71%, while the 200-Day Moving Average is calculated to be -49.81%.
Shares Statistics:
For the past three months, ADCT has traded an average of 943.38K shares per day and 563150 over the past ten days. A total of 96.69M shares are outstanding, with a floating share count of 77.58M. Insiders hold about 19.76% of the company’s shares, while institutions hold 69.74% stake in the company. Shares short for ADCT as of 1736899200 were 5178877 with a Short Ratio of 5.49, compared to 1734048000 on 4122662. Therefore, it implies a Short% of Shares Outstanding of 5178877 and a Short% of Float of 7.66.
